SS Innovations International, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsSS Innovations International, Inc. is a Florida-based medical device company commercializing the SSi Mantra surgical robotic system, primarily in India, with cumulative installations of 224 systems across 12 countries as of June 30, 2026.
What they do
SS Innovations develops, manufactures, and sells surgical robotic systems under the SSi Mantra brand, along with accessories and instruments under the SSi Mudra brand. The company commenced commercial sales in the second half of 2022 and has since focused on expanding its installed base in India and entering global markets. Manufacturing is based in India, which the company cites as a cost advantage.
Revenue drivers
- System sales (SSi Mantra) — Primary revenue source; Q2 2026 system sales were $12.4M, comprising 89% of quarterly revenue; 46 systems sold in H1 2026.
- Instrument sales — Recurring revenue from surgical instruments; Q2 2026 instrument sales were $1.1M, up 13% YoY.
- Warranty and lease income — Smaller ancillary streams; Q2 2026 warranty sales were $0.4M and lease income $16K.
Recent performance
Q2 2026 revenue rose 39.4% YoY to $13.9M, with gross margin of 50.9% (down from 59.1% in Q2 2025). Net loss widened to $2.7M from $0.3M in the prior-year quarter, driven by higher R&D expense ($2.4M vs. $0.5M) and SG&A. For H1 2026, revenue grew 65.6% to $25.0M, gross profit rose 77.5% to $12.4M, and net loss was $6.2M. The company had $13.6M cash (excluding restricted cash) and $0 long-term debt as of June 30, 2026.
Strategy
The company aims to expand its installed base in India and enter international markets, including the U.S. and EU, by obtaining regulatory approvals (FDA 510(k) and CE Mark). It is also developing new products and enhancements, focusing on affordability and accessibility. Management emphasizes clinical evidence, telesurgery capabilities, and physician training to drive adoption.
Risks
- Going concern — The company's financial statements express substantial doubt about its ability to continue as a going concern due to recurring losses and reliance on external financing.
- Regulatory approval delays — FDA 510(k) clearance is expected by Q1 2027 and CE Mark by end of 2026; any delay would postpone U.S. and EU market entry.
- Continued losses — Net losses have persisted since 2021, and the company expects losses to continue until it establishes consistent operational cash flows.
- Financing dependence — The company relies on capital raises to fund operations; inability to raise additional capital could limit expansion and R&D.
Outlook
Management expects revenue growth to continue, driven by SSi Mantra adoption in India and global expansion. Key near-term milestones include FDA 510(k) clearance for the SSi Mantra by end of Q1 2027 and CE Mark certification by end of 2026. The company plans to raise additional capital during the remainder of 2026.